OncoMatch

OncoMatch/Clinical Trials/NCT06361940

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Is NCT06361940 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Aromatase inhibitors or tamoxifen for breast cancer.

Phase 2RecruitingMedical College of WisconsinNCT06361940Data as of May 2026

Treatment: Aromatase inhibitors or tamoxifen — This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: ESR1 overexpression (≥1% positively staining cells by immunohistochemistry)

Estrogen and/or progesterone receptor positive tumor defined ≥1% positively staining cells by immunohistochemistry

Required: PR (PGR) overexpression (≥1% positively staining cells by immunohistochemistry)

Estrogen and/or progesterone receptor positive tumor defined ≥1% positively staining cells by immunohistochemistry

Required: HER2 (ERBB2) wild-type (negative by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH))

HER2 /neu must be negative by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH)

Disease stage

Required: Stage I, II (AJCC)

clinical stage I or II; AJCC clinical T4, N1-3 or M1, breast cancer [excluded]

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Cannot have received: any treatment for this breast cancer or for any malignancy diagnosed or treated within the past two years

Exception: non-melanomatous skin cancer, carcinoma in situ of the cervix

Patients must not have had a prior treatment for this breast cancer or for any malignancy diagnosed or treated within the past two years, with the exception of non-melanomatous skin cancer, carcinoma in situ of the cervix.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Froedtert Hospital and the Medical College of Wisconsin · Milwaukee, Wisconsin

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify